Список литературы
1.	Айсанов З.Р., Амиров Н.Б., Баранова О.П., Визель А.А., Визель И.Ю., Гурылева М.Э., Фаткуллин И.Ф., Чучалин А.Г. Саркоидоз. - М.: Издательский холдинг «Атмосфера», 2010. - 416 с. [Aisanov Z.R., Amirov N.B., Baranova O.P., Vizel А.А., Vizel I.Yu., Gurileva M.E., Fatkullin I.F., Chuchalin A.G. Sarcoidosis. Moscow: “Atmosphera”, 2010, 416 p. (In Russ.)]. https://elibrary.ru/item.asp?id=36987922
2.	Акопов А.Л., Баранова О.П., Богданов А.Н., Бондаренко И.Б., Двораковская И.В., Илькович М.М., Илькович Ю.М., Лучкевич В.С., Новикова Л.Н., Орлова Г.П., Орлов С.В. Интерстициальные и орфанные заболевания легких. - М.: ГЭОТАР-Медиа, 2016. - 560 с. [Akopov A.L., Baranova O.P., Bogdanov A.N., Bondarenko I.B., Dvorakovskaya I.V., Ilkovich M.M., Ilkovich Yu.M., Luchkevich V.S., Novikova L.N., Orlova G.P., Orlov S.V. Interstitial and orphan lung diseases. Moskow: GEOTAR-Media, 2016, 560 p. (In Russ.)]. https://elibrary.ru/item.asp?id=26227541
3.	Будкова А.И., Лапин С.В., Серебрякова М.К., Кудрявцев И.В., Тришина И.Н., Маслянский А.Л., Тотолян А.А. Субпопуляционный состав В-клеток периферической крови у больных системной красной волчанкой // Медицинская иммунология. - 2017. – Т. 19, № 2. – С. 175-184. [Budkova A.I., Lapin S.V., Serebriakova M.K., Kudryavtsev I.V., Trishina I.N., Maslyansky A.L., Totolian A.A. B-cell subpopulations of peripheral blood in systemic lupus erythematosus. Medical Immunology (Russia), 2017, Vol. 19, no. 2, pp. 175-184. (In Russ.)]. https://doi.org/10.15789/1563-0625-2017-2-175-184.
4.	Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян Арег А. Стандартизованная технология «Исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлюориметров-анализаторов» (Проект) // Медицинская иммунология. - 2012. - Т. 14, № 3. - С. 255-268. [Khaydukov S.V., Baydun L.A., Zurochka A.V., Totolian Areg A. Standardized technology «Research of lymphocytes subpopulation composition in peripheral blood using flow cytometry analyzers» (Draft). Medical Immunology (Russia), 2012, Vol. 14, no. 3, pp. 255-268. (In Russ.)]. http://dx.doi.org/10.15789/1563-0625-2012-3-255-268.
5.	Ando M., Goto A., Takeno Y., Yamasue M., Komiya K., Umeki K., Nureki S.I., Miyazaki E., Kadota J.I. Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis. Clin Rheumatol., 2018, Vol. 37, no. 10, pp. 2833-2838. doi: 10.1007/s10067-018-4183-2.
6.	Beccastrini E., Vannozzi L., Bacherini D., Squatrito D., Emmi L. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm., 2013, Vol. 21, no. 3, pp. 244-246. DOI: 10.3109/09273948.2012.762982.
7.	Beijer E., Veltkamp M., Meek B., Moller D.R.. Etiology and Immunopathogenesis of Sarcoidosis: Novel Insights. Semin Respir Crit Care Med., 2017, Vol. 38, no. 4, pp. 404-416. doi: 10.1055/s-0037-1603087.
8.	Belhomme N., Jouneau S., Bouzillé G., Decaux O., Lederlin M., Guillot S., Perlat A., Jégo P. Role of serum immunoglobulins for predicting sarcoidosis outcome: A cohort study. PLoS One, 2018, Vol. 13, no. 4, pp. e0193122. DOI: 10.1371/journal.pone.0193122.
9.	Belkhou A., Younsi R., Bouchti I., Hassani S. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine, 2008, Vol. 75, pp. 511–512. DOI: 10.1016/j.jbspin.2008.01.025.
10.	Bernstein K.E., Ong F.S., Blackwell W.L., Shah K.H., Giani J.F., Gonzalez-Villalobos R.A., Shen X.Z., Fuchs S., Touyz R.M. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev., 2012, Vol. 65, pp. 1-46. doi: 10.1124/pr.112.006809.
11.	Bomprezzi R., Pati S., Chansakul C., Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology, 2010, Vol. 75, pp. 568–570. doi: 10.1212/WNL.0b013e3181ec7ff9.
12.	Broos C.E., van Nimwegen M., Hoogsteden H.C., Hendriks R.W., Kool M., van den Blink B. Granuloma formation in pulmonary sarcoidosis. Front Immunol., 2013, Vol. 10, no 4, pp. 437. doi: 10.3389/fimmu.2013.00437.
13.	Cannon R.O., Cunnion R.E., Parrillo J.E., Palmeri S.T., Tucker E.E., Schenke W.H., Epstein S.E. Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain. J. Am. Coll. Cardiol., 1987, Vol. 10, pp. 190-200. doi: 10.1016/s0735-1097(87)80118-3.
14.	Casanova N., Zhou T., Knox K.S., Garcia J.G. Identifying novel biomarkers in sarcoidosis using genome-based approaches. Clin Chest Med., 2015, Vol. 36, pp. 621-630. doi: 10.1016/j.ccm.2015.08.005.
15.	Chopra A., Kalkanis A., Judson M.A. Biomarkers in sarcoidosis. Expert Rev Clin Immunol., 2016, Vol. 12, pp. 1191-1208. doi: 10.1080/1744666X.2016.1196135.
16.	Cinetto F., Compagno N., Scarpa R., Malipiero G., Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy, 2015, Vol. 13, no. 1, pp. 19. doi: 10.1186/s12948-015-0025-9.
17.	Csongrádi A., Enyedi A., Takács I., Végh T., Mányiné I.S., Pólik Z., Altorjay I.T., Balla J., Balla G., Édes I., Kappelmayer J., Tóth A., Papp Z., Fagyas M. Optimized angiotensin-converting enzyme activity assay for the accurate diagnosis of sarcoidosis. Clin Chem Lab Med., 2018, Vol. 56, no. 7, pp. 1117-1125. doi: 10.1515/cclm-2017-0837.
18.	Dasilva V., Breuil V., Chevallier P., Euller-Ziegler L. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine, 2010, Vol. 77, pp. 82–83. doi: 10.1016/j.jbspin.2009.11.005. 
19.	Duan J., Xu Y., Zhu H., Zhang H., Sun S., Sun H., Wang W., Xie S. Relationship between CT activity score with lung function and the serum angiotensin converting enzyme in pulmonary sarcoidosis on chest HRCT. Medicine (Baltimore), 2018, Vol. 97, no. 36, pp e12205. doi: 10.1097/MD.0000000000012205.
20.	Georas S.N., Chapman T.J., Crouser E.D. Sarcoidosis and T-helper cells. Th1, Th17, or Th17.1? Am. J. Respir. Crit. Care Med., 2016, Vol. 193, no. 11, pp. 1198–200. doi: 10.1164/rccm.201512-2419ED.
21.	Grosso S., Margollicci M.A., Bargagli E., Buccoliero Q.R., Perrone A., Galimberti D., Morgese G., Balestri P., Rottoli P. Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest., 2004, Vol. 64, pp. 57-62. doi: 10.1080/00365510410004092.
22.	Grutters J.C., Fellrath J.-M., Mulder L., Janssen R., van den Bosch J.M., van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest, 2003, Vol. 124, no. 1, pp. 186-195. doi: 10.1378/chest.124.1.186.
23.	Häggmark A., Hamsten C., Wiklundh E., Lindskog C., Mattsson C., Andersson E., Lundberg I.E., Grönlund H., Schwenk J.M., Eklund A., Grunewald J., Nilsson P. Proteomic profiling reveals autoimmune targets in sarcoidosis. Am J Respir Crit Care Med., 2015, Vol. 191, no. 5, pp. 574-583. doi: 10.1164/rccm.201407-1341OC.
24.	Huang H., Lu Z., Jiang C., Liu J., Wang Y., Xu Z. Imbalance between Th17 and regulatory T-Cells in sarcoidosis. Int J. Mol. Sci., 2013, Vol. 14, no. 11, pp. 21463-21473. doi: 10.3390/ijms141121463.
25.	Hunninghake G.W., Crystal R.G. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest., 1981, Vol. 67, no. 1, pp. 86-92. doi: 10.1172/JCI110036.
26.	Janiak P., Libert O., Vilaine J. P. Role of the renin-angiotensin system in neointima formation after injury in rabbits. Hypertension, 1994, Vol. 24, pp. 671-678. DOI: 10.1161/01.hyp.24.6.671.
27.	Kahkouee S., Samadi K., Alai A., Abedini A., Rezaiian L. Serum ACE Level in Sarcoidosis Patients with Typical and Atypical HRCT Manifestation. Pol J Radiol., 2016, Vol. 81, pp. 458-461. doi: 10.12659/PJR.897708.
28.	Kobak S., Yilmaz H., Sever F., Duran A., Sen N., Karaarslan A. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis., 2014, Vol. 2014, pp. 351852. doi: 10.1155/2014/351852.
29.	Kobak S., Ylmaz H., Sever F., Duran A., Sen N. Anti-cyclic citrullinated peptide antibodies in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis., 2014, Vol. 31, no. 3, pp. 206-210. https://www.ncbi.nlm.nih.gov/pubmed/25363220.
30.	Krause M.L., Cooper L.T., Chareonthaitawee P., Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford), 2016, Vol. 55, no. 1, pp. 189–191. doi: 10.1093/rheumatology/kev309.
31.	Lee N.S., Barber L., Akula S.M., Sigounas G., Kataria Y.P., Arce S. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol., 2011, Vol. 18, no. 8, pp. 1306-1316. doi: 10.1128/CVI.05118-11.
32.	Liu Y., Qiu L., Wang Y., Aimurola H., Zhao Y., Li S., Xu Z. The circulating Treg/Th17 cell ratio is correlated with relapse and treatment response in pulmonary sarcoidosis patients after corticosteroid withdrawal. PLoS One, 2016, Vol. 11, no. 2, pp. e0148207. doi: 10.1371/journal.pone.0148207.
33.	Mathur R.S., Kurdikar V.L., Shah J.R. Serum angiotensin converting enzyme in the diagnosis of pulmonary sarcoidosis. J Assoc Physicians India, 1990, Vol. 38, pp. 474–475. https://www.ncbi.nlm.nih.gov/pubmed/1963426.
34.	Miedema J.R., Kaiser Y., Broos C.E., Wijsenbeek M.S., Grunewald J., Kool M. Th17-lineage cells in pulmonary sarcoidosis and Löfgren's syndrome: Friend or foe? J Autoimmun., 2018, Vol. 87, pp. 82-96. doi: 10.1016/j.jaut.2017.12.012.
35.	O'Reilly P.J., Ding Q., Akthar S., Cai G., Genschmer K.R., Patel D.F., Jackson P.L., Viera L., Roda M., Locy M.L., Bernstein E.A., Lloyd C.M., Bernstein K.E., Snelgrove R.J., Blalock J.E. Angiotensin-converting enzyme defines matrikine-regulated inflammation and fibrosis. JCI Insight, 2017, Vol. 2, nn. 22, pp. 91923. doi: 10.1172/jci.insight.91923.
36.	Ors F., Gumus S., Aydogan M., Sari S., Verim S., Deniz O. HRCT findings of pulmonary sarcoidosis; relation to pulmonary function tests. Multidiscip Respir Med., 2013, Vol. 8, pp. 8. doi: 10.1186/2049-6958-8-8.
37.	Palchevskiy V., Hashemi N., Weigt S.S., Xue Y.Y., Derhovanessian A., Keane M.P., Strieter R.M., Fishbein M.C., Deng J.C., Lynch J.P., Elashoff R., Belperio J.A. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenesis Tissue Repair, 2011, Vol. 4, pp. 10. doi: 10.1186/1755-1536-4-10.
38.	Popević S., Šumarac Z., Jovanović D., Babić D., Stjepanović M., Jovičić S., Šobić-Šaranović D., Filipović S., Gvozdenović B., Omčikus M., Milovanović A., Videnović-Ivanov J,, Radović A,, Žugić V., Mihailović-Vučinić V. Verifying sarcoidosis activity: chitotriosidase versus ace in sarcoidosis— case-control study. J Med Biochem, 2016, Vol. 35, pp. 390-400. doi: 10.1515/jomb-2016-0017.
39.	Rauch M., Tussiwand R., Bosco N., Rolink A.G. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One, 2009, Vol. 4, pp. e5456. doi: 10.1371/journal.pone.0005456.
40.	Sakthivel P., Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr. Opin. Hematol., 2017, Vol. 24, no. 1, pp. 59-65. doi: 10.1097/MOH.0000000000000301.
41.	Saussine A., Tazi A., Feuillet S., Rybojad M., Juillard C., Bergeron A., Dessirier V., Bouhidel F., Janin A., Bensussan A., Bagot M., Bouaziz J.D. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One, 2012, Vol. 7, no. 8, pp. 43588. doi: 10.1371/journal.pone.0043588.
42.	Stohl W., Xu D., Kim K.S., Koss M.N., Jorgensen T.N., Deocharan B., Metzger T.E., Bixler S.A., Hong Y.S., Ambrose C.M., Mackay F., Morel L., Putterman C., Kotzin B.L., Kalled S.L. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum., 2005, Vol. 52, pp. 2080–2091. doi: 10.1002/art.21138.
43.	Ten Berge B., Paats M.S., Bergen I.M., van den Blink B., Hoogsteden H.C., Lambrecht B.N., Hendriks R.W., Kleinjan A. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford), 2012, Vol. 51, no. 1, pp. 37-46. doi: 10.1093/rheumatology/ker316.
44.	Ueda-Hayakawa I., Tanimura H., Osawa M., Iwasaka H., Ohe S., Yamazaki F., Mizuno K., Okamoto H. Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology (Oxford), 2013, Vol. 52, no. 9, pp. 1658–1666. doi: 10.1093/rheumatology/ket186.
45.	Vorselaars A.D., van Moorsel C.H., Zanen P., Ruven H.J., Claessen A.M., van Velzen-Blad H., Grutters J.C. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med., 2015, Vol. 109, pp. 279-285. doi: 10.1016/j.rmed.2014.11.009.
46.	Weinberg I., Vasiliev L., Gotsman I. Anti-dsDNA antibodies in sarcoidosis. Semin Arthritis Rheum., 2000, Vol. 29, no. 5, pp. 328-331. https://www.ncbi.nlm.nih.gov/pubmed/10805357.
47.	Weir E.K. Hypoxic pulmonary vasoconstriction. Chest, 1982, Vol. 82., pp. 519-521.